Pantaleo et al. constructed the expanded IFNγ-induced immune signature (EIIS) [102] and T-cell-inflamed signature (TIS) in GIST [102], both of which are related to clinical benefit of ICIs treatment and considered as predictors of immunotherapy [187, 188]. This evidence concerns the gene IFNG and gastrointestinal stromal tumor.